Saturday, July 5, 2025 7/5/2025

SOCS domain-mediated fibronectin matrix degradation on fibrosis reversal

Award Number: R15HL154051
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/01/2021
PERIOD OF PERFORMANCE END DATE: 07/31/2025

Group Awards By:

View Award Description

SOCS domain-mediated fibronectin matrix degradation on fibrosis reversal - ABSTRACT Idiopathic Pulmonary fibrosis (IPF) is an irreversible lung disease with no effective treatment options. Insurance claims data on IPF incidence between years 2001-2011 was estimated at 31-43 per 100,000 per year, translating to 89,000 patients living with IPF in the United States in the year 2000 and 34,000 new cases diagnosed per year. IPF is a disease of unknown etiology and myriad environmental factors are known to contribute to the development of the disease in susceptible individuals. During fibrosis, fibroblasts differentiate into myofibroblast cells that produce vast amounts of extracellular matrix (ECM) proteins that alter matrix rigidity and lung architecture impacting lung function. A critical constituent of the ECM is the core matrisome protein fibronectin (FN) that assembles into a FN matrix contributing to Collagen matrix formation and ECM rigidity. Von Hippel Lindau (VHL) protein is required for the FN matrix formation and is upregulated in the lungs of IPF patients. We have shown that the SOCS domain (Suppressors Of Cytokine Signaling), a 40 amino acid conserved domain in the SOCS family of proteins, targets VHL for degradation by a cullin-dependent ubiquitin ligase mechanism. We hypothesize that SOCS domain overexpression in myofibroblasts will result in degradation of the pathologic FN matrix in myofibroblasts and fibrosis reversal. We will perform these experiments using lung fibroblasts transduced with the SOCS domain and the SOCS domain mutant that is defective in VHL degradation. Using RNAseq and phosphoproteome analysis, we will develop a computational pipeline to identify probable signaling mediators in the process of myofibroblast reversal. Our in vitro findings, will be evaluated in a Bleomycin-induced in vivo mouse model of lung fibrosis to test the efficiency of fibrosis reversal by adenoviral-mediated delivery of the SOCS domain. We expect a reduction of fibrosis markers in our in vitro experiments and significant reversal of fibrosis in our in vivo model. The results from these experiments will offer new peptide based targets as well as provide therapeutic agents that can be used either on its own or in combination with existing therapies to reverse matrix formation and fibrosis.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2021	NORTHERN ARIZONA UNIVERSITY	601 S KNOLES DR RM 220	FLAGSTAFF	AZ	86011	COCONINO	USA	Cardiovascular Diseases Research	000	1	6/21/2024	NEW	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $469,034 )
2021	2021	NORTHERN ARIZONA UNIVERSITY	601 S KNOLES DR ROOM 220	FLAGSTAFF	AZ	86011	COCONINO	USA	Cardiovascular Diseases Research	000	1	7/27/2021	NEW	$469,034
														Subtotal = $469,034

Grand Total All Awards = $469,034

Top

All Categories

About

Search

Reports

Data Submission

Award Information

SOCS domain-mediated fibronectin matrix degradation on fibrosis reversal

Award Number: R15HL154051

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/01/2021

PERIOD OF PERFORMANCE END DATE: 07/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer